Frontiers of Chemical Science and Engineering >
High-level expression of recombinant IgG1 by CHO K1 platform
Received date: 03 May 2015
Accepted date: 10 Aug 2015
Published date: 30 Sep 2015
Copyright
The Chinese Hamster Ovary (CHO K1) cell was used to express a targeted anti-cancer monoclonal antibody by optimizing the platform of the construction of production cell line in this study. The adherent CHO K1 was first adapted to suspension culture in chemical defined medium. Then the glutamine synthetase (GS) vector was applied to construct a single plasmid to overexpress a monoclonal antibody IgG1. Post transfection, the production of cell pool was optimized by glutamine-free selection and amplification using various concentrations of methionine sulfoximine. The best cell pool of CHO K1/IgG1 was used to screen the top single clone using the limiting dilution cloning. Finally, a high IgG1 production of 780 mg/L was obtained from a batch culture. This study demonstrated that the construction of high producing cell line, from gene to clone, could be completed within six month and the gene amplification improved protein production greatly.
Ningning Xu , Jianfa Ou , Al-Karim (Al) Gilani , Lufang Zhou , Margaret Liu . High-level expression of recombinant IgG1 by CHO K1 platform[J]. Frontiers of Chemical Science and Engineering, 2015 , 9(3) : 376 -380 . DOI: 10.1007/s11705-015-1531-5
| 1 |
Leone-Bay A. Next-generation protein therapeutics summit conference report. Therapeutic Delivery, 2011, 2(10): 1233–1234
|
| 2 |
Leader B, Baca Q J, Golan D E. Protein therapeutics: A summary and pharmacological classification. National Review, 2008, 7(1): 21–39
|
| 3 |
Zhou L, Xu N, Sun Y, Liu X M. Targeted biopharmaceuticals for cancer treatment. Cancer Letters, 2014, 352(2): 145–151
|
| 4 |
Edelman G M. Antibody structure and molecular immunology. Science, 1973, 180(4088): 830–840
|
| 5 |
Chames P, Regenmortel M V, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 2009, 157: 220–233
|
| 6 |
Butler M, Spearman M. The choice of mammalian cell host and possibilities for glycosylation engineering. Current Opinion in Biotechnology, 2014, 30: 107–112
|
| 7 |
Zhang P, Chan K F, Haryadi R, Bardor M, Song Z. CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy. Advances in Biochemical Engineering/Biotechnology, 2013, 131: 63–87
|
| 8 |
Lai T, Yang Y, Ng S K. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals, 2013, 6(5): 579–603
|
| 9 |
Omasa T, Onitsuka M, Kim W D. Cell engineering and cultivation of Chinese Hamster Ovary (CHO) cells. Current Pharmaceutical Biotechnology, 2010, 11(3): 233–240
|
| 10 |
Lewis N E, Liu X, Li Y, Nagarajan H, Yerganian G, O’Brien E, Bordbar A, Roth A M, Rosenbloom J, Bian C, Xie M, Chen W, Li N, Baycin-Hizal D, Latif H, Forster J, Betenbaugh M J, Famili I, Xu X, Wang J, Palsson B O. Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nature Biotechnology, 2013, 31(8): 759–765
|
| 11 |
Florian M. Wurm. CHO quasispecies—Implications for manufacturing processes. Processes, 2013, 1: 296–311
|
| 12 |
Cruz Edmonds M C, Tellers M, Chan C, Salmon P, Robinson D K, Markusen J. Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Molecular Biotechnology, 2006, 34(2): 179–190
|
| 13 |
Xu X, Nagarajan H, Lewis N E, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen M R, Neff N, Passarelli B, Koh W, Fan H C, Wang J, Gui Y, Lee K H, Betenbaugh M J, Quake S R, Famili I, Palsson B O, Wang J. The genomic sequence of the Chinese Hamster Ovary (CHO)-K1 cell line. Nature Biotechnology, 2011, 29(8): 735–741
|
| 14 |
Jerums M, Yang X. Optimization of cell culture media. BioProcess International, 2005, Supplement: 38–44
|
| 15 |
Dale L L. Mammalian expression cassette engineering for high-level protein production. BioProcess International, 2006, 4(5): 14–23
|
| 16 |
Kingston R E, Kaufman R J, Bebbington C R, Rolfe M R. Amplification using CHO cell expression vectors. Current Protocols in Molecular Biology. Hoboken: John Wiley & Sons, 2002
|
| 17 |
Porter AJ, Dickson AJ, Racher AJ. Strategies for selecting recombinant CHO cell lines for cGMP manufacturing. Realizing the potential in bioreactors. Biotechnology Progress, 2010, 26(5): 1446–14554
|
| 18 |
Harraghy N, Regamey A, Girod P A, Mermod N. Using matrix attachment regions to improve recombinant protein production. Methods in Molecular Biology, 2012, 801: 93–110
|
| 19 |
Hou J J, Hughes B S, Smede M, Leung K M, Levine K, Rigby S, Gray P P, Munro T P. High-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system. New Biotechnology, 2014, 31(3): 214–220
|
| 20 |
Nair A R, Jinger X, Hermiston T W. Effect of different UCOE-promoter combinations in creation of engineered cell lines for the production of Factor VIII. BMC Research Notes, 2011, 4(178): 1–8
|
| 21 |
Lequin R. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clinical Chemistry, 2005, 51(12): 2415–2418
|
| 22 |
Meng Y G, Liang J, Wong W L, Chisholm V. Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells. Gene, 2000, 242: 201–207
|
| 23 |
Clarke J, Porter A, Davis J M. Cloning. Animal cell culture. New York: John Wiley & Sons, 2011, 231–254
|
/
| 〈 |
|
〉 |